文献速递肝病

拉维达韦联合索磷布韦治疗初治和经治慢性丙型肝炎基因4型患者的疗效

Effectiveness of ravidasvir plus sofosbuvir in interferon-naïve and treated patients with chronic hepatitis C genotype-4.
PubMed 文献 · J Hepatol · 2017-09-19

本研究在300例慢性HCV基因4型感染患者中评估拉维达韦联合索磷布韦的疗效与安全性,分三组:初治伴或不伴代偿性Child-A肝硬化(组1)、干扰素经治无肝硬化(组2)、干扰素经治伴肝硬化(组3)。组1和组2随机加或不加基于体重的利巴韦林治疗12周,组3均加利巴韦林并随机接受12周或16周疗程。主要终点为治疗结束后12周持续病毒学应答(SVR12),298例入组患者中总体SVR12为95.3%。

要点

  • 298例入组患者总体SVR12为95.3%,无肝硬化者98%,肝硬化者91%。
  • 利巴韦林使用与否及既往干扰素治疗史均不影响SVR12率。
  • 未观察到病毒学突破,研究治疗耐受性良好。

核心结论

  • 拉维达韦联合索磷布韦,联合或不联合利巴韦林,耐受性良好,在伴或不伴肝硬化的HCV-GT4感染患者中(无论既往是否接受干扰素治疗)均获得高持续病毒学应答率。

研究设计与样本

  • 共招募300例HCV-GT4感染患者,分为三组:组1为初治伴或不伴代偿性Child-A肝硬化患者;组2为干扰素经治无肝硬化患者;组3为干扰素经治伴肝硬化患者。
  • 组1和组2接受拉维达韦200 mg每日一次联合索磷布韦400 mg每日一次治疗12周,并按1:1随机加或不加基于体重的利巴韦林。
  • 组3接受拉维达韦联合索磷布韦加利巴韦林,并按1:1随机接受12周或16周疗程。
  • 主要终点为治疗结束后12周持续病毒学应答(SVR12)。
  • 实际入组298例:组1 149例,组2 79例,组3 70例。

主要发现

  • 所有开始研究治疗的患者中95.3%达到SVR12,包括无肝硬化患者98%和肝硬化患者91%,无论初治或干扰素经治。
  • 利巴韦林使用与否及既往干扰素治疗史均不影响SVR12率。
  • 未观察到病毒学突破,研究治疗耐受性良好。

临床怎么用

  • 原文结论认为拉维达韦联合索磷布韦(联合或不联合利巴韦林)在伴或不伴肝硬化的HCV-GT4感染患者中(无论既往是否接受干扰素治疗)耐受性良好且与高持续病毒学应答率相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Although treatment of hepatitis C virus (HCV) and HCV-genotype-4 (GT4) has become very effective, it remains very expensive, and affordable options are needed, especially in limited resource countries. The aim of this study was to assess the efficacy and safety of the combination of ravidasvir (an NS5A inhibitor) and sofosbuvir to treat patients with chronic HCV-GT4 infection. METHODS: A total of 300 patients with HCV-GT4 infection were recruited in three groups: treatment-naïve patients with or without compensated Child-A cirrhosis (Group 1); interferon-experienced patients without cirrhosis (Group 2); and interferon-experienced patients with cirrhosis (Group 3). Groups 1 and 2 received ravidasvir 200 mg QD plus sofosbuvir 400 mg QD for 12 weeks and were randomized 1:1 to treatment with or without weight-based ribavirin. Group 3 patients received ravidasvir plus sofosbuvir with ribavirin and were randomized 1:1 to a treatment duration of 12 weeks or 16 weeks. The primary endpoint was sustained virologic response at 12 weeks post-treatment (SVR12). RESULTS: A total of 298 patients were enrolled: 149 in Group 1, 79 in Group 2 and 70 in Group 3. SVR12 was achieved in 95.3% of all patients who started the study, including 98% of patients without cirrhosis and 91% of patients with cirrhosis, whether treatment-naïve or interferon-experienced. Ribavirin intake and history of previous interferon therapy did not affect SVR12 rates. No virologic breakthroughs were observed and the study treatment was well tolerated. CONCLUSIONS: Treatment with ravidasvir plus sofosbuvir, with or without ribavirin, was well tolerated and associated with high sustained virologic response rate for HCV-GT4 infected patients with and without cirrhosis, regardless of previous interferon-based treatments. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov Identifier: NCT02371408. LAY SUMMARY: This study evaluated efficacy and safety of the new oral hepatitis C drug ravidasvir in combination with the approved oral drug sofosbuvir in 298 patients infected with hepatitis C type 4. Our results showed that treatment with ravidasvir plus sofosbuvir, with or without ribavirin, was well tolerated and associated with high response rate in patients with and without cirrhosis.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Esmat G, Elbaz T, El Raziky M, et al. Effectiveness of ravidasvir plus sofosbuvir in interferon-naïve and treated patients with chronic hepatitis C genotype-4. J Hepatol. 2017. PMID: 28935432. doi:10.1016/j.jhep.2017.09.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。